Literature DB >> 30598497

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.

Stephanie Sasse1, Katharina Reddemann2, Arjan Diepstra3, Sven Borchmann4,5,6, Ilske Oschlies2, Antje Schnitter2, Andreas Engert4, Peter Borchmann4, Wolfram Klapper7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30598497      PMCID： PMC6312031          DOI： 10.3324/haematol.2018.207829

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study.

Authors:  Mariano Provencio; Clara Salas; Isabel Millán; Blanca Cantos; Antonio Sánchez; Carmen Bellas
Journal:  Leuk Lymphoma       Date:  2010-09

2.  Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Authors:  Stephanie Sasse; Katharina Reddemann; Arjan Diepstra; Ilske Oschlies; Antje Schnitter; Sven Borchmann; Andreas Engert; Peter Borchmann; Wolfram Klapper
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

3.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

4.  Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.

Authors:  Ayako Sakakibara; Kei Kohno; Ahmed E Eladl; Teerada Klaisuwan; Eri Ishikawa; Yuka Suzuki; Satoko Shimada; Masato Nakaguro; Yoshie Shimoyama; Taishi Takahara; Seiichi Kato; Naoko Asano; Shigeo Nakamura; Akira Satou
Journal:  Histopathology       Date:  2018-03-09       Impact factor: 5.087

Review 5.  Mechanisms of resistance to immune checkpoint inhibitors.

Authors:  Russell W Jenkins; David A Barbie; Keith T Flaherty
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640
  5 in total
  1 in total

1.  Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.

Authors:  Tomohiro Aoki; Lauren C Chong; Katsuyoshi Takata; Katy Milne; Ashley Marshall; Elizabeth A Chavez; Tomoko Miyata-Takata; Susana Ben-Neriah; Doria Unrau; Adele Telenius; Merrill Boyle; Andrew P Weng; Kerry J Savage; David W Scott; Pedro Farinha; Sohrab P Shah; Brad H Nelson; Christian Steidl
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.